Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Ascelia Pharma - What happened during Q1?

By HC Andersen Capital
Ascelia Pharma

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 21 May 2024 at 1:00 PM when she gives investors an update on Q1 2024.

After the closing of Q1, Ascelia Pharma confirmed that SPARKLE image reading has been completed and expects headline results in first half of May 2024. Furthermore, the company announced that they have exercised the 2nd tranche of loan facility with Formue Nord Fokus A/S.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./ Claus Thestrup 13.24 PM 23-04-2024.

Recent videos

Sitowise: Changes in management
09.02.2026 klo 10.48 Sitowise Group
Valmet Q4'25: Cautious guidance overshadowed strong profitability
06.02.2026 klo 15.40 Valmet
Kreate, Q4'25 (in English)
06.02.2026 klo 12.00 Kreate Group
QleanAir, Audiocast, Q4'25
06.02.2026 klo 11.00 QleanAir
Vitec Software Group, Audiocast, Q4'25
06.02.2026 klo 11.00 Vitec Software Group
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.